United States· US:68727-745_25abb1d8-f921-4aae-8240-1914cd80417a
VYXEOS
A cytarabine and daunorubicin product containing cytarabine; daunorubicin, registered in United States by Jazz Pharmaceuticals, Inc.. The same ATC class is registered in 13 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Cytarabine and daunorubicin is registered in 13 of 19 countries.
Countries holding a registration under ATC L01XY01 (cytarabine and daunorubicin), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 8 of them publish a price we can compare per daily dose
Cytarabine and daunorubicin · ATC L01XY01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- CYTARABINE; DAUNORUBICIN
- Manufacturer
- Jazz Pharmaceuticals, Inc.
- Country
- United States (US)
- ATC code
- L01XY01
- ATC class
- Cytarabine and daunorubicin
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 4
- ndc11687277450120 mL in 1 VIAL (68727-745-01)
- ndc11687277450240 mL in 1 CARTON (68727-745-02)
- ndc1168727-745-01
- ndc1168727-745-02
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Cytarabine and daunorubicin in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaVYXEOS LIPOSOMALJazz Pharmaceuticals Ireland Ltd, Dublin
- SwitzerlandVyxeos liposomal 44 mg/100 mg, Pulver für ein Konzentrat zur Herstellung einer InfusionsdispersionJazz Pharmaceuticals Switzerland GmbH
- FinlandVyxeos liposomalJazz Pharmaceuticals Ireland Limited
- United KingdomVyxeos liposomal 44mg/100mg powder for concentrate for solution for infusion vialsJazz Pharmaceuticals UK Ltd
- IrelandVyxeos liposomal 44 mg/100 mg powder for concentrate for solution for infusionJazz Pharmaceuticals Ireland Limited
- IcelandVyxeos liposomalJazz Pharmaceuticals Ireland Ltd
- NetherlandsVyxeos liposomal 44 mg/100 mg poeder voor concentraat voor oplossing voor infusieJazz Pharmaceuticals Ireland Limited
- NorwayVyxeos liposomalJazz Pharmaceuticals Ireland Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vyxeos Liposomal
- Liechtenstein · Vyxeos Liposomal
- Norway · Vyxeos Liposomal
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7814fa06-4adb-4fc7-bcf8-0c3fd451b778 GET /v1/drugs/7814fa06-4adb-4fc7-bcf8-0c3fd451b778?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "100; 44",
"substance": "CYTARABINE; DAUNORUBICIN",
"productndc": "68727-745",
"dosage_form": "INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION",
"dea_schedule": null,
"strength_unit": "mg/20mL; mg/20mL",
"application_number": "NDA209401",
"marketing_category": "NDA"
}See everything about cytarabine and daunorubicin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.